• FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

  • FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

  • FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

  • FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

1234
Who We Are:

Learn about our commitment to FGFR-driven diseases

Our Product:

Discover the role of FGFR inhibition

Genetic Growth Disorder:

Learn about PROPEL and PROPEL 2

Latest Press Releases

09.29.2021

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

05.28.2021

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

03.31.2021

BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration To Co-Develop and Commercialize Infigratinib in Oncology